The global Systemic Lupus Erythematosus Market size is expected to reach USD 3.08 billion
by 2025, according to a new report by Grand View Research, Inc., exhibiting a
CAGR of 7.0% during the forecast period.Introduction of new biological
therapies, which will add to treatment alternatives and medication costs, in
the development pipeline is estimated to fuel revenue generation of the market.
Certain new promising drugs that are currently in Phase III trials are
anticipated to augment the market as these drugs may target the lupus nephritis
patient subset with few effective alternatives and significant unmet needs to
be met. This factor is likely to have a strong impact on the market as nearly
50.0% of SLE patients suffer with lupus nephritis.
Use of approved biologic,
Benlysta, through clinical studies, has revealed drastic improvements and
substantial decrease in consumption of anti-inflammatory glucocorticoids in
moderate SLE cases. GSK’s current initiatives center on further increasing
opportunities for Benlysta. The company is conducting indication expansion
clinical trials, combination therapy studies with rituximab, and new product
development, to widen opportunities for its therapy. In this direction, recent
launch of Benlysta’s subcutaneous formulation in several countries is expected
to boost the SLE market over the forecast period.
Full Research Report On Systemic Lupus Erythematosus
Market Analysis:
www.grandviewresearch.com/industry-analysis/systemic-lupus-erythematosus-sle-market
www.grandviewresearch.com/industry-analysis/systemic-lupus-erythematosus-sle-market
Further key findings from the study suggest:
·
North America was the major
contributor for the SLE market revenue in 2017 and is anticipated to rise at a
CAGR of 8.1% during the forecast period. This is due to availability of reimbursement
and better healthcare infrastructure and accessibility to biologics.
·
Europe was ranked as the second
largest regional market in the SLE market in 2017 and is expected to register a
CAGR of 5.5% over the forecast period
·
Immunosuppressants held the
largest share in the market in 2017 due to their low cost and high
accessibility, whereas the biologics segment is projected to post the highest
CAGR during the same period
·
In 2017, the oral segment held
the dominant share of over 54.0% in the market, followed by the intravenous
segment that requires trained medical personnel for administration. Over the
forecast years, the latter is poised to expand at a CAGR of 10.4%
·
Key players in this space
include GlaxoSmithKline, Roche, Pfizer, Novartis, Bayer, and Sanofi. By 2025,
other companies such as ImmuPharma, Aurinia Pharmaceuticals, and Astra Zeneca
are anticipated to enter the SLE market.
Browse More Reports Of This Category By
Grand View Research At: https://www.grandviewresearch.com/industry/pharmaceuticals
Grand View Research has segmented the
global systemic lupus erythematosus market by drug class, route of
administration, and region:
Systemic Lupus Erythematosus
Drug Classes Outlook (Revenue, USD Million, 2014 - 2025)
·
NSAIDs
·
Corticosteroids
·
Antimalarials
·
Immunosuppressants
·
Biologics
Systemic Lupus Erythematosus
Route of Administration Outlook (Revenue, USD Million, 2014 - 2025)
·
Oral
·
Intravenous
·
Subcutaneous
Systemic Lupus Erythematosus
Regional Outlook (Revenue, USD Million, 2014 - 2025)
·
North America
o
U.S.
o
Canada
·
Europe
o
U.K.
o
Germany
o
France
o
Italy
o
Spain
o
Greece
o
Sweden
o
Norway
o
Poland
o
RoE
·
Asia Pacific
o
Japan
o
China
o
Hong Kong
o
Taiwan
o
South Korea
o
New Zealand
o
Australia
o
India
o
Malaysia
o
Singapore
·
Latin America
o
Brazil
o
Mexico
o
Argentina
·
MEA
o
Turkey
o
Saudi Arabia
o
Kuwait
o
Israel
o South Africa
Access Full
Press Release of this Report:
About Grand View Research
Grand View Research, Inc. is a U.S.
based market research and consulting company, registered in the State of
California and headquartered in San Francisco. The company provides syndicated
research reports, customized research reports, and consulting services. To help
clients make informed business decisions, we offer market intelligence studies
ensuring relevant and fact-based research across a range of industries, from
technology to chemicals, materials and healthcare.
For more information: www.grandviewresearch.com
